Daiichi Sankyo Company and Ranbaxy Laboratories announced today that the latter's New Drug Discovery Research has been transferred to Daiichi Sankyo India Pharma Private Limited as part of the strategy to strengthen the global research and development (R&D) structure of the Daiichi Sankyo Group.
Established in 1994, the New Drug Discovery Research has high-level synthetic chemical research capabilities. According to the stock exchange announcement, the transaction has been approved by the Department of Scientific and Industrial Research, Ministry of Science and Technology.
The new organisation, Daiichi Sankyo Life Science Research Center in India, based in Gurgaon, will play a key role in the Group's global Drug Discovery research to create promising new drugs especially in the area of low molecular weight infections and inflammatory disease treatments.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app